The decision to automate an ovarian malignancy risk panel on your analyzer comes down to one fundamental distinction: the source of the algorithm’s inputs. The Risk of Malignancy Index (RMI) requires a clinical imaging variable—ultrasound findings—that lies outside the immunoassay laboratory’s direct control. The Risk of Ovarian Malignancy Algorithm (ROMA) operates using only laboratory-derived quantitative blood markers (HE4 and CA125) alongside menopausal status, making it uniquely suited for full integration into an automated immunoassay platform.
Both algorithms assess ovarian malignancy risk, but ROMA was designed for automation from the ground up. Its reliance on nothing more than two serum immunoassay results and a demographic field means diagnostic manufacturers can embed the calculation directly into analyzer software. RMI, in contrast, will always contain a manual bottleneck due to its required ultrasound score, fundamentally limiting its suitability for a fully automated panel.
The Input Difference: Clinical vs. Laboratory-Controlled Data
The most salient difference for panel development is not the clinical sensitivity or specificity of the algorithms, but the type and origin of the data they consume. One algorithm can be fully realized within the closed environment of a chemistry analyzer; the other cannot.
RMI’s Dependency on Ultrasound Findings
RMI combines CA125 serum levels, an ultrasound-based morphological score, and menopausal status. The ultrasound score is a subjective, real-time clinical assessment made by a sonographer or radiologist. It evaluates features like cyst wall structure, septations, and solid areas. This data point never originates from a blood sample or a laboratory instrument. To calculate an RMI score on an automated platform, you would need to either integrate with hospital imaging systems—a massive interoperability undertaking—or force a laboratory technician to manually enter a value derived from a clinical report. Both approaches break the seamless workflow that automation is meant to deliver.
ROMA’s Purely Biochemical Basis
ROMA is calculated from just three inputs: quantitative serum HE4 (pmol/L), quantitative serum CA125 (kU/L), and the patient’s menopausal status (pre- or post-). Crucially, both HE4 and CA125 are measured from the same blood draw using immunoassay techniques. Menopausal status is a simple, binary demographic field that can be entered once during patient registration. This means the entire algorithm can be executed by the analyzer itself as soon as the last immunoassay result is generated. There is no external dependency, no interpretive variable, and no need for a human bridge between two separate worlds of clinical data.
Impact on Automated Workflow Design
This difference in input data propagates directly into the system architecture your development team must build. It dictates whether you can deliver a true “sample-to-answer” experience.
Why RMI Resists Full Automation
Attempting to automate RMI creates a data integration problem, not just an assay problem. The analyzer would have to wait for a value it cannot generate, stalling the automated workflow. Even with HL7 interfacing, the ultrasound report is often free-text or structured in a radiology module, not a discrete numeric field designed for algorithmic consumption. The result is that any “automated RMI” panel would still rely on manual data entry at the point of care or in the LIS middleware. This introduces typing errors, delays, and limits the scalability of the test across the network.
How ROMA Enables Embedded Algorithmic Scoring
By developing synchronized HE4 and CA125 immunoassay reagents, manufacturers can calibrate both assays to run on the same platform, from the same sample, in the same analytical batch. The analyzer’s onboard computer then applies the ROMA predictive index formula, using the pre-set menopausal status, and reports a single, numerical risk score immediately. This process is identical to how other calculated tests—like estimated GFR or free androgen index—are already automated on modern clinical chemistry platforms. It turns an ovarian cancer risk assessment into a routine, high-throughput laboratory parameter.
Understanding the Trade-offs
Building a ROMA-capable panel is more demanding on reagent development and software validation. The automation benefits come with a stringent set of technical requirements.
Reagent Harmonization is Non-Negotiable
The ROMA formula assumes that the HE4 and CA125 values are harmonized and traceable to the methods used in the clinical validation studies. If you source these reagents from different suppliers or develop them on different lot-to-lot stability timelines, the combined risk score can drift unpredictably. Your development program must include rigorous cross-reagent stability studies, onboard calibration curves that are co-validated, and locked master curve files that ensure batch-to-batch consistency for both assays simultaneously.
The Hidden Variable: Menopausal Status
Menopausal status is the one human-entered variable in an otherwise fully automated chain. Different ROMA models use a specific age cutoff (often 50 years) as a surrogate if true status is unknown. Your analyzer software must be configured to either accept a discrete “pre/post/unknown” selection or apply the age-based default rule transparently. Failure to handle this cleanly in the middleware can lead to misclassification, eroding clinical trust in the automated score. It’s a trivial-seeming detail that has major risk-management implications.
Making the Right Choice for Your Panel Development Strategy
Your decision must align with the core value proposition of your automated diagnostic platform: delivering reliable, walk-away results without manual intervention.
- If your primary focus is a fully automated, sample-to-answer ovarian risk panel: Commit to the ROMA algorithm. It requires the co-development of HE4 and CA125 reagents and strict harmonization, but it allows you to embed a proven malignancy risk score directly into the analyzer’s results stream.
- If your platform must support clinicians who rely on ultrasound correlation: You can still offer CA125 as a standalone parameter, but positioning an “automated RMI panel” is misleading. It will always demand a manual ultrasound score input, creating a mixed workflow that undermines the very efficiency your instrument promises.
ROMA’s isolation of risk assessment to the serum sample is the key that unlocks true automation; RMI’s clinical imaging requirement keeps it chained to a manual, multi-disciplinary workflow. Your panel development roadmap must reflect this fundamental architectural reality, not fight against it.
Summary Table:
| Feature / Parameter | RMI (Risk of Malignancy Index) | ROMA (Risk of Ovarian Malignancy Algorithm) |
|---|---|---|
| Data Sources | CA125 + Ultrasound Score + Menopausal Status | Serum HE4 + Serum CA125 + Menopausal Status |
| Data Origin | Mixed (Laboratory + Radiology/Clinical) | Purely Laboratory-Derived (Serum Immunoassay) |
| Automation Feasibility | Low (Manual bottleneck due to imaging input) | High (Fully integrable onboard analyzer score) |
| Workflow Efficiency | Requires manual entry or complex PACS/LIS bridge | Automated sample-to-answer processing |
| Key IVD Development Need | System integration across external clinical data | Strict HE4 & CA125 reagent harmonization |
Developing an automated ROMA or ovarian cancer immunoassay panel? CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. From harmonized HE4 and CA125 reagents to assay validation support, we help you streamline automated panel development. Contact CamelBio today to accelerate your diagnostic pipeline!